Plasma Replacement Therapy for Alzheimer's Disease

Alzheimer’s disease(AD)is the most common neurode-generative disease that affects memory,thinking,behavior,and the ability to perform everyday activities.It has been estimated that more than 35 million people worldwide suffered from AD in 2018[1],and this figure continues to grow.Unfortunately,no cure or treatment that slows the progression of the disease has been discovered despite extensive efforts from academics and the pharmaceutical industry.Most drug trials for AD have targeted the 13-amyloid protein[2],which accumulates in this disease,and the failure of amyloid-based drugs to impact on cognition in people with AD has led to re-questioning of the amyloid hypothesis of AD,and has provided a fresh impetus to explore alternative therapeutic strategies.